Epibiotech
Epibiotech EPI-001 Approval by the Ministry of Food and Drug Safety Update (12/21/2023) As of December 21st, 2023, Epibiotech has been approved by the Ministry of Food and Drug Safety to start Phase 1/2a clinical trials for its EPI-001 autologous dermal papilla cell treatment to treat androgenetic alopecia. Safety will be measured in Phase 1…
Read More
Epibiotech continues to announce important milestones and progress leading up to a Phase 1 clinical trial for its cell therapy in AGA. Innovative Drug Discovery For Hair-Loss Therapy Symposium Earlier this year in June, Epibiotech co-hosted a hair loss research conference in South Korea with Yonsei University’s Pharmaceutical Research Institute. The meeting, titled “Innovative Drug…
Read More
In this article we will hear about recent advances made by Epibiotech in their efforts to create an effective cell therapy for hair growth. Korean Biotech Specializing In Hair Follicle Research Below is a quick video displaying the company atmosphere at Epibiotech. This video is also shared on the homepage of Epibiotech’s website. Note, the…
Read More